HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Biochips” Screen For Toxicity Without Use Of Animals

This article was originally published in The Rose Sheet

Executive Summary

Emerging "biochip" technology that assesses the toxicity of chemicals to humans in vitro could be of use to personal-care firms faced with an approaching ban on animal testing in Europe

You may also be interested in...



European Commissioner Gives Update On Movement To Replace Animal Tests

Freer communication and a stronger spirit of solidarity among European stakeholders, in addition to the continued participation of colleagues in the U.S. and Japan, are critical to advancing the development of non-animal test strategies, according to European Commissioner for Science and Research Janez Poto?nik

FDA and EC Agree To Collaborate On Validation Of Animal Testing Alternatives

FDA and the European Commission have struck an agreement to work together more closely in peer reviewing validation studies of alternative methods to animal tests for cosmetics, according to the European Cosmetic Toiletry and Perfumery Association (Colipa)

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel